Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. From left to right: Michael ...

A biomechanical ship that resembles a wingless dragonfly, Lexx is the most powerful weapon of destruction in the two universes. It can talk, achieve ludicrous speeds, and has a tail, all of which put ...

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients ...

Lexaria’s after-hours surge came after the company filed with the Securities and Exchange Commission on Thursday, revealing that it had ended its “Capital on Demand” Sales Agreement with JonesTrading ...

With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of human afflictions, including ...

We are initiating coverage of Lexaria Bioscience Corp. (NASDAQ:LEXX) with a valuation of $15.00 per share. This present value is based on cash flows related to probability adjusted estimates related ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms ...